These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 22741201)

  • 1. [Good preclinical study, as an obligatory stage in design and clinical use of new medicinal preparations].
    Vasil'ev AN
    Antibiot Khimioter; 2012; 57(1-2):41-9. PubMed ID: 22741201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Preclinical data as basis for the design of clinical studies].
    Fichtner I
    Onkologie; 2008; 31 Suppl 2():34-8. PubMed ID: 18487867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug research: from the idea to the product.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1997 Dec; 35(12):541-52. PubMed ID: 9455711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The scope and requirements related to preclinical and clinical studies of a new medicinal product, including biotechnological and biosimilar products.
    Brodniewicz-Proba T
    Acta Pol Pharm; 2008; 65(6):641-5. PubMed ID: 19172845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Responsibilities of clinical pharmacology in the early phase of drug development].
    Kuhlmann J
    Med Klin (Munich); 2000 May; 95(1 Spec No):31-40. PubMed ID: 10851846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Potential of Adaptive Design in Animal Studies.
    Majid A; Bae ON; Redgrave J; Teare D; Ali A; Zemke D
    Int J Mol Sci; 2015 Oct; 16(10):24048-58. PubMed ID: 26473839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical-pharmacological aspects to accelerate the development process from the preclinical to the clinical phase/1st communication: The contribution of clinical pharmacology].
    Kuhlmann J
    Arzneimittelforschung; 2004; 54(5):251-8. PubMed ID: 15212186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of an NIH consortium for preclinicAl AssESsment of CARdioprotective therapies (CAESAR): a paradigm shift in studies of infarct size limitation.
    Lefer DJ; Bolli R
    J Cardiovasc Pharmacol Ther; 2011; 16(3-4):332-9. PubMed ID: 21821536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacology should be at the centre of all preclinical and clinical studies on new psychoactive substances (recreational drugs).
    Green AR; Nutt DJ
    J Psychopharmacol; 2014 Aug; 28(8):711-8. PubMed ID: 24674814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New insights into drug development for pediatric solid tumors: what preclinical data justify clinical trials in pediatric cancer?
    Houghton PJ
    Expert Rev Anticancer Ther; 2013 Oct; 13(10):1135-8. PubMed ID: 24093514
    [No Abstract]   [Full Text] [Related]  

  • 12. Correct assessment of new compounds using in vivo screening models can reduce false positives.
    Bueters TJ; Hoogstraate J; Visser SA
    Drug Discov Today; 2009 Jan; 14(1-2):89-94. PubMed ID: 18840543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The current requirements for the preclinical study of the safety of new drugs].
    Arzamastsev EV; Liubimov BI
    Eksp Klin Farmakol; 1995; 58(3):7-12. PubMed ID: 7663306
    [No Abstract]   [Full Text] [Related]  

  • 14. Recent advances and novel strategies in pre-clinical formulation development: an overview.
    Shah AK; Agnihotri SA
    J Control Release; 2011 Dec; 156(3):281-96. PubMed ID: 21763367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Strategy of molecular drug design: hits, leads and drug candidates].
    Guo ZR
    Yao Xue Xue Bao; 2008 Sep; 43(9):898-904. PubMed ID: 19048779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Similar biological medicinal products currently licensed in the European union--overview of non-clinical study programs.
    Heim HK
    Biologicals; 2011 Sep; 39(5):284-8. PubMed ID: 21871818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical predictors of clinical safety: opportunities for improvement.
    Sistare FD; DeGeorge JJ
    Clin Pharmacol Ther; 2007 Aug; 82(2):210-4. PubMed ID: 17507920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tyrosine kinase inhibitor (TKI)-induced cardiotoxicity: approaches to narrow the gaps between preclinical safety evaluation and clinical outcome.
    Yang B; Papoian T
    J Appl Toxicol; 2012 Dec; 32(12):945-51. PubMed ID: 22961481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reproductive toxicology guidelines: comparison and application.
    Beltrame D; Mazué G
    Ann Ist Super Sanita; 1993; 29(1):3-14. PubMed ID: 8129269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abuse liability assessment in preclinical drug development: predictivity of a translational approach for abuse liability testing using methylphenidate in four standardized preclinical study models.
    Teuns GB; Geys HM; Geuens SM; Stinissen P; Meert TF
    J Pharmacol Toxicol Methods; 2014; 70(3):295-309. PubMed ID: 24632211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.